Skip Navigation

European Heart Journal 2004 25(15):1300-1309; doi:10.1016/j.ehj.2004.05.022
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Deedwania, P. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deedwania, P. C
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical research

Efficacy, safety and tolerability of ß-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure

Prakash C Deedwaniaa, Stephen Gottliebb, Jalal K Ghalic, Finn Waagsteind and John CM Wikstrandd,*,1 for the MERIT-HF Study Group

a University of California, San Francisco School of Medicine, San Francisco, CA, USA
b University of Maryland, Baltimore, USA
c Cardiac Centers of Louisiana, Shreveport, Louisiana, USA
d Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg, Sweden

Received February 19, 2004; revised April 23, 2004; accepted May 6, 2004 * Corresponding author. Tel.: +46-31-342-2936; fax: +46-31-413447
E-mail address: john.wikstrand{at}wlab.gu.se

Aim To study the efficacy and tolerability of ß-blockade in elderly patients with heart failure in the MERIT-HF study.

Methods and results Cox proportional hazards model was used to calculate hazard ratios (HR) with 95% confidence intervals (CI). Risk reduction was defined as (1-HR). In patients >=65 years total mortality was reduced by 37% (95% CI 17% to 52%; ), sudden death by 43% (95% CI 17% to 61%; ), and death from worsening heart failure by 61% (95% CI 32% to 77%; ). Hospitalisations for worsening heart failure was reduced by 36% . Elderly patients with severe heart failure (NYHA class III/IV with ejection fraction 0.25; , and patients above 75 years showed similar risk reductions. Metoprolol CR/XL was safe and well tolerated both during initiating therapy and during long-term follow-up.

Conclusions Metoprolol CR/XL was easily instituted, safe and well tolerated in elderly patients with systolic heart failure. The data suggest that these are the patients in whom treatment will have the greatest impact as shown by number of lives saved and number of hospitalisations avoided. The time has come to overcome the barriers that physicians perceive to ß-blocker treatment, and to provide it to the large number of elderly patients with heart failure in need of this therapy.

Key Words: Heart failure • ß-Blockade • Prognosis • Tolerability • Elderly


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart J SupplHome page
E. Erdmann
Safety and tolerability of beta-blockers: prejudices and reality
Eur. Heart J. Suppl., March 1, 2009; 11(suppl_A): A21 - A25.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. Pfisterer, P. Buser, H. Rickli, M. Gutmann, P. Erne, P. Rickenbacher, A. Vuillomenet, U. Jeker, P. Dubach, H. Beer, et al.
BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial
JAMA, January 28, 2009; 301(4): 383 - 392.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
F. Follath
Beta-blockade today: the gap between evidence and practice
Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C28 - C34.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. G. Le Couteur, L. Bailey, and V. Naganathan
Beta-blockers and heart failure in older people
Eur. Heart J., April 1, 2006; 27(7): 887 - 888.
[Full Text] [PDF]


Home page
JAMAHome page
D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis
Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure
JAMA, September 14, 2005; 294(10): 1240 - 1247.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. C. Burger and H. B.-L. Rocca
Pharmacotherapy of Congestive Heart Failure in Elderly Patients
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 85 - 94.
[Abstract] [PDF]


Home page
Evid. Based Med.Home page
R. Lehman
Evidently...
Evid. Based Med., February 1, 2005; 10(1): 8 - 8.
[Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., February 1, 2005; 10(1): 31 - 32.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. D. Flather, M. C. Shibata, A. J.S. Coats, D. J. Van Veldhuisen, A. Parkhomenko, J. Borbola, A. Cohen-Solal, D. Dumitrascu, R. Ferrari, P. Lechat, et al.
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
Eur. Heart J., February 1, 2005; 26(3): 215 - 225.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. McMurray
Making sense of SENIORS
Eur. Heart J., February 1, 2005; 26(3): 203 - 206.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.